mRNA regulations
mRNA Regulatory Landscape
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA32Sep 15, 2026
mRNA analytics
The mRNA Therapeutics Analytical Landscape
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA10Sep 15, 2026
mRNA / analytical
The mRNA Therapeutics Analytical Landscape
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA3Aug 28, 2026
Market Drivers
mRNA Therapeutics Market
April Stanley, MS MBA
Nice Insight
NI-8-28-MA-22Aug 27, 2026
Market Drivers
Market Drivers of the RNA Landscape
April Stanley, MS MBA; David Alvaro, Ph.D.
Nice Insight
NI-8-26-MA20Aug 26, 2026
Prevention
Preventive Therapeutics Beyond Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-13Aug 18, 2026
Vaccine Development
New Vaccine Technologies Expand the Frontiers of Prevention and Treatment
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-11Aug 14, 2026
Thermostable Vaccine
Thermostable Vaccines and the Future of Global Distribution
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-07Aug 10, 2026
Asia Manufacturing
APAC Expands Specialized Manufacturing Capabilities Across High-Value Modalities
Pharma's Almanac
PAO-08-26-PA-02Aug 3, 2026
Vaccines
The Next Generation of Vaccine Platforms
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-01Aug 3, 2026
RNA
Is mRNA a Gene Therapy? Unpacking the Evolving Regulatory Debate
April Stanley, MS MBA; Cynthia A. Challener, Ph.D.
Nice Insight
PAO-03-25-NI-06Mar 26, 2025
Nice Insight Reports
Biotech Funding Ups and Downs
April Stanley, MS MBA
Nice Insight
PAO-04-24-NI-01Apr 2, 2024
Column: M&A
Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.
Nigel Walker
Nice Insight
PAO-06-022--NI-12Jun 24, 2022
Genetic Vaccines
Working to Overcome Analytical Challenges Posed by Genetic Vaccines
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-21-NI-01Jun 4, 2021